How much funding has Mission Therapeutics raised?

Mission Therapeutics has raised $130.6M in total funding, most recently a Venture Round.

Who are Mission Therapeutics's investors?

Mission Therapeutics's investors include Pfizer Ventures, Imperial Innovations, Sofinnova Partners, SR One, IP Group, Roche.

When was Mission Therapeutics founded?

Mission Therapeutics was founded in 2011.

Where is Mission Therapeutics headquartered?

Mission Therapeutics is headquartered in Cambridge, United Kingdom.

What industry is Mission Therapeutics in?

Mission Therapeutics operates in Biotech, Healthcare.

How many employees does Mission Therapeutics have?

Mission Therapeutics has 11-50 employees.

Mission Therapeutics

Promoting mitochondrial health through targeted DUB inhibition

Cambridge, United Kingdom · Founded 2011 · $130.6M raised

Biotech

Healthcare

Headquarters: Cambridge
Employees: 11–50
Founded: 2011
Business Model: B2B

Website: missiontherapeutics.com
Total Funding: $130.6M
Last Round: $13.3M Venture RoundOct 2025
Rounds: 5

About

Mission Therapeutics is a private drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat diseases of high unmet need. The company is a world leader in discovering and developing novel therapeutics that promote the removal of dysfunctional mitochondria through a process called mitophagy. Its lead candidates, MTX325 and MTX652, both target USP30, a deubiquitylating enzyme that can retard cellular quality control processes. MTX325 is being developed for Parkinson's disease and MTX652 for acute kidney injury. Founded in 2011 by Niall Martin, Steve Jackson, and Xavier Jacq, Mission Therapeutics is headquartered in Cambridge, UK, and has raised over £117 million in funding from leading life science investors.

Summary

Mission Therapeutics is a Biotech company based in Cambridge, United Kingdom, founded in 2011. It has raised $130.6M in total across 5 rounds, most recently a $13.3M Venture Round round in Oct 2025. Investors include Pfizer Ventures, Imperial Innovations and Sofinnova Partners.

LinkedIn X (Twitter)